Description

Bio-Techne’s $311.4 Million Revenue Base — Biotech Recovery Could Reshape Growth!

Bio-Techne Corporation reported mixed third-quarter fiscal 2026 results amid uneven end-market conditions. Total revenue declined 2% organically and on a reported basis to $311.4 million, affected by timing of large OEM commercial supply orders and purchases from two major cell therapy customers that received FDA Fast Track Designations. Excluding these timing effects, underlying organic growth was approximately 2%. Adjusted operating margin improved 310 basis points sequentially to 34.2% but declined 70 basis points year-over-year due mainly to unfavorable product mix and volume deleverage. Adjusted EPS was $0.53, slightly below the prior year. Large pharmaceutical customers remained strong, delivering low double-digit growth supported by spending on discovery, translational research, and manufacturing. The U.S. academic market showed stabilization and modest growth, aided by a slightly higher NIH budget and grant activity. Emerging biotechnology customers remained weak, with high single-digit revenue declines despite improving biotech funding.